Targeting TROP2 in Oncology: Pan-Tumor Insights and the Next Wave of ADC Innovation

0:00-13:24

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Publisher

CME in Minutes: Education in Oncology & Hematology

Link

answersincme.com/NHB860

Published

September 18, 2026

Duration

13 min

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

Answers in CME

CI

CME in Minutes: Education in Oncology & Hematology

@cmeinminuteseducationinoncol

#targetingtrop2 #tumorinsights #adcinnovation #lifesciences #medicine

The Nile